Crispr Therapeutics AG vs Public Storage — how do they compare? Crispr Therapeutics AG trades at $53.26 (market cap $4.88B), while Public Storage trades at $286.07 (market cap $53.35B). The key difference: Public Storage is far larger — about 10.9× Crispr Therapeutics AG's market cap, and Public Storage pays a 4.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Public Storage for 130 Days on average.
| CRSP | PSA | |
|---|---|---|
Market Cap | $4.88B | $53.35B |
Volume | 2,861,747 | 1,176,034 |
Sector | Health | Real Estate |
52-Week High | $74.92 | $330.47 |
52-Week Low | $44.34 | $258.44 |
Typical Hold Time | 77 Days | 130 Days |
Enterprise Value | $3.30B | $67.62B |
Dividend Yield | — | 4.2% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Public Storage (PSA) trades at $286.07, up 1.45% with recent earnings beats and strong profitability metrics including 41.8% net income margin. Technical indicators show bearish momentum with support at $277, while fundamentals reveal stable revenue growth and a $3.00 dividend. The company recently completed its Public Storage Canada acquisition and issued C$400 million in senior notes.
The stock presents a mixed outlook with analyst consensus target of $328.33 offering 15% upside, though technical weakness and valuation premiums pose risks. Key opportunities include operational momentum and reliable yield, while headwinds include oversupply concerns and interest rate sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →